Syros Pharmaceuticals, Inc.

As of October 31, 2024, Syros Pharmaceuticals, Inc. is considered overvalued and has been downgraded from risky to does not qualify due to poor financial metrics, including a negative price to book value and significant underperformance compared to the S&P 500.

As of March 5, 2025, Syros Pharmaceuticals, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators present mixed signals, suggesting a cautious outlook.

As of March 2022, the management team of Syros Pharmaceuticals, Inc. includes Independent Chairman Mr. Peter Wirth, President and CEO Dr. Nancy Simonian, and Directors Dr. S. Gail Eckhardt, Dr. Richard Young, Dr. Srinivas Akkaraju, Mr. Mark Alles, and Ms. Marsha Fanucci. They are responsible for the company's strategic direction and operations.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene control medicines for cancer and monogenic diseases. As of September 2024, it has a market cap of $0.64 million and reported a net profit of -$6 million.

As of Jun 18, Syros Pharmaceuticals, Inc. has a market capitalization of 0.64 million, with net sales of 0.39 million and a net profit of -97.82 million over the last four quarters. As of Dec'23, the company reported shareholder's funds of 16.66 million and total assets of 168.17 million.